Scrip takes a look at what a listing of Mankind Pharma, which has thrice the revenues of Pfizer’s India unit and the fourth largest domestic pharma sales, would mean. A GPCR-based candidate against type-2 diabetes and obesity is in Phase I trials and a search on India’s trial registry reveals a study for an ayurvedic preparation against diabetes

The Chinese biopharma industry is eager to use the latest artificial intelligence technology to boost efficiency and lighten workloads, as companies deal with drastic change and look to improve their understanding of foreign markets. Meanwhile, senior European leaders called for a level playing field during a recent visit to China.

Junshi is the latest Chinese company to announce plans to expand into Southeast Asia, where its compatriot firms are also eyeing large market potential and are set to benefit from less stringent reviews of China-only clinical data due to fewer questions around ethnic differences versus the US.

CSPC Pharmaceutical's SYS6006 has gained an emergency use authorization in China less than one year after entering clinical trials, becoming the first mRNA vaccine for COVID-19 to be approved in the country.